Journal of Clinical Densitometry
Volume 13, Issue 1 , Pages 56-62 , January 2010

Risedronate on 2 Consecutive Days a Month Reduced Vertebral Fracture Risk at 1Year Compared With Historical Placebo

  • Nelson B. Watts

      Affiliations

    • Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA
    • Corresponding Author InformationAddress correspondence to: Nelson B. Watts, MD, Department of Internal Medicine, University of Cincinnati, Piedmont Avenue, Suite 6300, Cincinnati, OH 45219.
    • ,
  • Jacques P. Brown

      Affiliations

    • Department of Medicine, Laval University, Quebec City, PQ, Canada
    • ,
  • Gary Cline

      Affiliations

    • ICON plc, Biostatistics, North Wales, PA, USA

Received 31 March 2009 ,Revised 16 September 2009 ,Accepted 16 September 2009.

References 

  1. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999;282:1344–1352
  2. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000;11:83–91
  3. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 1999;42:2309–2318
  4. Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res. 2000;15:1006–1013
  5. Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int. 2000;67:277–285
  6. van den Boogaard CH, Breekveldt-Postma NS, Borggreve SE, et al. Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study. Curr Med Res Opin. 2006;22:1757–1764
  7. Downey TW, Foltz SH, Boccuzzi SJ, et al. Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. South Med J. 2006;99:570–575
  8. Cramer JA, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005;21:1453–1460
  9. Van Staa TP, Geusens P, Leufkens HGM, et al. Persistence to bisphosphonate treatment in actual clinical practice. Bone. 2005;37:S412
  10. Akesson K, Beusterien K, Hebborn A, et al. Strong patient preference for once-monthly over weekly oral bisphosphonate dosing in postmenopausal osteoporosis. Bone. 2005;37:S417
  11. Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin. 2005;21:1895–1903
  12. Delmas PD, Benhamou CL, Man Z, et al. Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. Osteoporos Int. 2008;19:1039–1045
  13. Cleophas TJ, Zwinderman AH. Limitations of randomized clinical trials. Proposed alternative designs. Clin Chem Lab Med. 2000;38:1217–1223
  14. Rosner F. The ethics of randomized clinical trials. Am J Med. 1987;82:283–290
  15. Watts NB, Lindsay R, Li Z, et al. Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate. Osteoporos Int. 2003;14:437–441
  16. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077–2082
  17. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282:637–645
  18. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535–1541
  19. Chesnut CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. PROOF Study Group. Am J Med. 2000;109:267–276
  20. Genant HK, Wu CY, Van Kuik C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8:1137–1147
  21. Sorensen OH, Crawford GM, Mulder H, et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone. 2003;32:120–126
  22. Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int. 2002;71:103–111
  23. Delmas PD, McClung MR, Zanchetta JR, et al. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone. 2008;42:36–42
  24. Gehan EA. The evaluation of therapies: historical control studies. Stat Med. 1984;3:315–324
  25. Pocock SJ. The combination of randomized and historical controls in clinical trials. J Chronic Dis. 1976;29:175–188

 Conflict of interest: Dr. Nelson B. Watts receives honoraria and consulting fees through the University of Cincinnati Bone Health and Osteoporosis Center and research support from Procter & Gamble Pharmaceuticals and sanofi-aventis. Dr. Jacques P. Brown receives honoraria for lecturing and consultancies as well as grants and research support for clinical trials sponsored by sanofi-aventis Canada and Procter & Gamble Pharmaceuticals. Dr. Gary Cline was an employee of Procter & Gamble Pharmaceuticals. He also owns stock in Procter & Gamble Pharmaceuticals.

PII: S1094-6950(09)00234-0

doi: 10.1016/j.jocd.2009.09.005

Journal of Clinical Densitometry
Volume 13, Issue 1 , Pages 56-62 , January 2010

Article Tools

* Image Usage & Resolution